ACT-001 (Accendatech): a LY96 inhibitors, PAI-1 inhibitors, TLR4 antagonists Drug, Initially developed by Accendatech Co. Ltd., ACT-001 was donated by Accendatech (Tianjin, China). Antibodies to α-SMA, fibronectin, NF-κB p65 (specific to phosphor S536), and GAPDH, as well as appropriate secondary antibodies were purchased from Abcam (USA). ACT-001 (Accendatech): 一种LY96抑制剂、PAI-1抑制剂、TLR4拮抗剂药物，由Accendatech Co. Ltd. (天津尚德药缘科技股份有限公司)公司最早进行研发，目前全球最高研发状态为临床3期，作用机制: LY96抑制剂 (lymphocyte antigen 96 inhibitors),PAI-1抑制剂 (纤维蛋白溶酶原激活质抑制物-1. ACT001, which is currently in phase I clinical trials for the treatment of glioblastoma (GBM). However, the detailed molecular mechanism of ACT001 is still unclear. In this study, we. Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. Subscribe or buy profile to access the full content and links. Using its internal drug discovery platform, Accendatech has developed some first-in-class therapeutics that are in various development phases. Accendatech is developing ACT-001 as a treatment for recurrent glioblastoma multiforme (GBM). (Sourced from: ) The drug development strategy of Accendatech is focused on identifying and commercializing the unique pharmacological properties of natural compounds including, but not limited to, those form. ACT-001 is under clinical development by Accendatech and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). ACT001 is the first-in-class therapeutics as a dual inhibitor targeting both the NF-κB and STAT3 pathways that are involved in many pathological processes. The safety profile of ACT001 has been demonstrated by an array of clinical studies in adults and pediatric patients.